This company has been acquired
Pardes Biosciences Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Pardes Biosciences's earnings have been declining at an average annual rate of -1.6%, while the Biotechs industry saw earnings growing at 23.7% annually.
Wichtige Informationen
-1.6%
Wachstumsrate der Gewinne
45.8%
EPS-Wachstumsrate
| Biotechs Wachstum der Industrie | 17.0% |
| Wachstumsrate der Einnahmen | n/a |
| Eigenkapitalrendite | -49.0% |
| Netto-Marge | n/a |
| Letzte Ertragsaktualisierung | 30 Jun 2023 |
Jüngste Aktualisierungen vergangener Leistungen
Keine Aktualisierungen
Recent updates
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate
Jul 18
Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation
Jan 20We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully
Oct 01Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19
Sep 13Pardes Biosciences GAAP EPS of -$0.48
Aug 15Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans
Jun 14Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform
Jan 21Aufschlüsselung der Einnahmen und Ausgaben
Wie Pardes Biosciences Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -76 | 26 | 57 |
| 31 Mar 23 | 0 | -93 | 28 | 70 |
| 31 Dec 22 | 0 | -97 | 29 | 70 |
| 30 Sep 22 | 0 | -87 | 27 | 61 |
| 30 Jun 22 | 0 | -75 | 23 | 52 |
| 31 Mar 22 | 0 | -55 | 17 | 38 |
| 31 Dec 21 | 0 | -39 | 10 | 28 |
| 30 Sep 21 | 0 | -36 | 7 | 21 |
| 30 Jun 21 | 0 | -27 | 4 | 15 |
| 31 Mar 21 | 0 | -20 | 2 | 9 |
Qualität der Erträge: PRDS is currently unprofitable.
Wachsende Gewinnspanne: PRDS is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: Insufficient data to determine if PRDS's year-on-year earnings growth rate was positive over the past 5 years.
Beschleunigtes Wachstum: Unable to compare PRDS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: PRDS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-31.3%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: PRDS has a negative Return on Equity (-49%), as it is currently unprofitable.